🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Humira Biosimilars Arrive in Europe linkedin.com/pulse/humira-b…

Check out my latest article: Biotech CEOs: Can Scientist-Founders Stay In Charge? linkedin.com/pulse/biotech-… via LinkedIn

‘Scientific wellness’ still searching for a business model nature.com/articles/d4158…. There's a way to go, I agree Eric Topol. Yet I'm glad there is still optimism Dr. Leroy Hood

Inside BenevolentAI: the $2bn tech company backed by Neil Woodford on.ft.com/2IshuCR So disappointed. So not what UK biotech - and UK PLC - needs right now.

#ICER using its growing influence to shame the authors of UPIs - unsupported price increases. Does the acronym make it official? bit.ly/2VmCWh8

Little dig at payers' blocking biosimilars in revised ICER RA report p. 16, 37. bit.ly/2AZyxHE Patients must fail originator before qualifying for biosimilar (?!) So the originator is cheaper, and different. System is working well, then.

A for augmented, S is for sensible spelling: I get that machines are clever, but names like "nference" and "Qrativ" might even catch them out as they comb through unstructured text.... Maybe that's the idea...bit.ly/36zfuSE

Should #Biotech incubation rates have a ceiling, if they don't already? (talent/time) Some in #venturecapital thinking about this: early-stage funding gets ahead of later-stage patient $$ (seems unlikely now, but we've all seen the cycles...)

UK-based carer tells me today: “I have worked in this industry for 33 years. We are now getting recognition for what we do. It is overwhelming.” Am ashamed it took a global pandemic. #coronavirus #carers #coronasilverlinings

COVID-19 Winners and Losers: triage begins by sector, sub-sector, investor & company linkedin.com/pulse/covid-19…

Triage has started: linkedin.com/pulse/covid-19…

Wake-up call for EU from COVID-19: half of European citizens are overweight or obese, says Frans Muller, CEO of food retailer (!) Delhaize, on #FTGlobalBoardroom

Pricing remdesivir "well below value" is the "right and responsible" thing to do as the world reels from this pandemic bit.ly/31vCDFV How far and wide might that idea spread - particularly if the world keeps reeling in 2021 and beyond...?

Check out my latest article: Virtual healthcare may change the pharma marketing leaderboard linkedin.com/pulse/virtual-… via LinkedIn

Melanie Senior, who authored the guide, comments on the UK #biotech opportunity. Melanie Senior #InvestinBiotech

Invest in biotech bioindustry.org/policy/invest-…

Check out my latest article: Move over, Pfizer: Moderna grabs vaccine spotlight linkedin.com/pulse/move-ove… via LinkedIn

#InvestinBiotech 'Twas a good year, 2020, at least from the perspective of investment into biotech - UK, US, China and elsewhere. Great work BioIndustry Association (BIA); glad to be involved. Look out for more Nature Biotechnology shortly on the global funding picture.

Dodgy data AND a 56k price tag? Really? Just as the pharma industry rep was recovering. Shame, because it could well be an important advance but it hasn’t yet proven that. Biogen says it is “driven to address patient needs” ... not sure this approval and price tag reflects that.

Countdown to Biotech Hangout hangout where I join biotech top brass including Daphne Zohar @JSchimmer_E Bruce Booth et al to talk M&A, financing…and some regulatory data points (expanded in forthcoming Nature Biotechnology)